Protocol Ledger

NCT04750226 · Phase III · COMPLETED

Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

Interventional Phase III clinical trial protocol NCT04750226 sponsored by AbbVie in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-02-18 Enrollment: 118 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04750226
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)118 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04750226
Protocol FieldVerified Registry Value
NCT IdentifierNCT04750226
Consolidated Lead SponsorAbbVie
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment118 participants (ACTUAL)
Registered Start Date2021-02-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI